News & Updates

Show Multimedia Only

Older age, overweight raise risk of symptomatic VTE in DFF patients

16 Jul 2026 by

A Singapore study has observed a high prevalence of symptomatic venous thromboembolism (VTE) in patients who underwent distal femur fracture (DFF) surgery. Those with advanced age or who are overweight are more likely to develop symptomatic VTE.

Older age, overweight raise risk of symptomatic VTE in DFF patients

16 Jul 2026

Calcium-enriched permeate supplement prevents bone loss in postmenopausal women

14 Jul 2026

Daily intake of calcium-enriched permeate (CP) supplement in two doses is comparably effective as taking calcium carbonate (CC) in suppressing bone turnover markers and maintaining bone mineral density (BMD) in postmenopausal women with vitamin D sufficiency, reveals a study, noting that inulin offers no additional advantage.

Calcium-enriched permeate supplement prevents bone loss in postmenopausal women

14 Jul 2026

Air pollution exposure a risk factor for late-onset rheumatoid arthritis

12 Jul 2026

Exposure to fine particulate matter (PM) appears to contribute to an increased risk of rheumatoid arthritis incidence after age 65 years, as shown in a study.

Air pollution exposure a risk factor for late-onset rheumatoid arthritis

12 Jul 2026

Electroacupuncture offers symptom relief in knee OA

09 Jul 2026 by

Electroacupuncture appears beneficial to patients with knee osteoarthritis (OA), having been shown to provide substantial and durable symptom relief in a randomized controlled trial.

Electroacupuncture offers symptom relief in knee OA

09 Jul 2026

Pulse steroid therapy tied to bone turnover marker suppression, but not BMD loss

06 Jul 2026 by

Pulse intravenous methylprednisolone does not induce short-term loss of lumbar spine or hip bone mineral density (BMD), reports a Singapore study. However, it does suppress bone turnover markers, suggesting early effects on bone remodelling that are not captured by BMD alone.

Pulse steroid therapy tied to bone turnover marker suppression, but not BMD loss

06 Jul 2026

Use of sotatercept in a patient with transplant-ineligible PAH on dual therapy

04 Jul 2026 by

This is a case of a 64-year-old woman with pulmonary arterial hypertension (PAH) poorly controlled on dual therapy, who was intolerant of selexipag and unsuitable for lung transplantation.